Home › Research › Drug development
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging
Pittock RR, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR, Vemuri P, Lowe VJ et al.. Neurology, 2023-08-16
Topic: Amyloid, tau and blood-test diagnosis
Background and objectives Treatment options for Alzheimer disease (AD) are limited and have focused mainly on symptomatic therapy and improving quality of life. Recently, lecanemab, an anti-β-amyloid monoclonal antibody (mAb), received accelerated approval by the US Food and Drug Administration for treatment in the early stages of biomarker-confirmed symptomatic AD. An additional anti-β-amyloid mAb, aducanumab, was approved in 2021, and more will potentially become available in the near future.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Pittock, R. R., Aakre, J. A., Castillo, A. M., Ramanan, V. K., Kremers, W. K., Jack, C. R., et al. (2023). Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging. Neurology. https://doi.org/10.1212/wnl.0000000000207770
Vancouver
Pittock RR, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR, et al. Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging. Neurology. 2023. doi:10.1212/wnl.0000000000207770. PMID: 37586881.
BibTeX
@article{pittock2023-37586881,
author = {Pittock, R. R. and Aakre, J. A. and Castillo, A. M. and Ramanan, V. K. and Kremers, W. K. and Jack, C. R. and Vemuri, P. and Lowe, V. J. and others},
title = {{Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging}},
journal = {Neurology},
year = {2023},
doi = {10.1212/wnl.0000000000207770},
pmid = {37586881},
url = {https://doi.org/10.1212/wnl.0000000000207770}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Recently, lecanemab, an anti-β-amyloid monoclonal antibody (mAb), received accelerated approval by the US Food and Drug Administration for treatment in the early stages of biomarker-confirmed symptomatic AD.
- An additional anti-β-amyloid mAb, aducanumab, was approved in 2021, and more will potentially become available in the near future.
- Research on the applicability and generalizability of the anti-β-amyloid mAb eligibility criteria on adults with biomarkers available in the general population has been lacking.
- The study's primary aim was to apply the clinical trial eligibility criteria for lecanemab treatment to participants with early AD of the population-based Mayo Clinic Study of Aging (MCSA) and assess the generalizability of anti-amyloid treatment.
Why it matters
This cross-sectional study took the eligibility rules used in the lecanemab clinical trial and applied them to people with early Alzheimer's disease in the population-based Mayo Clinic Study of Aging. Its aim was to see how well those trial rules carry over to adults in the general population, which the authors say had not been studied. It looks at who could qualify for anti-amyloid treatment, not at whether the treatment works.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designcross-sectional
- Effect size54.9%; 97.5%; 47.3%
- Evidence strengthLow
How this study scored 60/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Neurology) |
| Journal's citation record | 4 / 4 | Neurology: journal h-index 525 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 150 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 30.0 citations a year over 5 year(s) since 2023 |
| Impact for its field and year | 5 / 6 | Cited 21.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 20 other studies in this library |
| Still being cited | 3 / 4 | Cited 142 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Maria E. Vassilaki: h-index 45 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Chicago: institution h-index 1,769 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 37586881) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.
Later studies that cite this one
20 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Drug development
Also in Drug development
106 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.